Plain-English translation of NCT04518501 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether Fuzuloparib, a newer type of cancer medication, works better when combined with arsenic trioxide in patients whose ovarian cancer has returned and is no longer responding to chemotherapy. Lab studies have shown that these two medications together may be more effective at stopping cancer cell growth than either medication alone. The goal is to see if this combination can help people with this difficult-to-treat form of cancer.
Many people with ovarian cancer experience a recurrence and need new treatment options, but current medications don't work well for everyone. This medication combination was discovered in laboratory studies to have a synergistic effect—meaning the two drugs work together more powerfully than separately—and researchers want to test whether this benefit translates to helping real patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would take Fuzuloparib capsules and arsenic trioxide tablets by mouth as part of this study. The trial is enrolling 50 patients and will evaluate whether the combination treatment is safe and effective for your type of cancer. You would need to visit the research site for regular check-ups, blood tests, and imaging scans to monitor how you are responding to the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China